MYCOLab Ai Logo - gold and army green

Introduction to XIV updating course of antimicrobials and infectious diseases

Summary

Healthcare professionals gathered at a major conference in Madrid to learn about the latest advances in treating infections caused by antibiotic-resistant bacteria and other pathogens. The course highlighted new antibiotic combinations that work against previously untreatable infections, faster ways to identify infections in emergency rooms and intensive care units, and modern treatment strategies based on scientific evidence. Speakers emphasized the importance of using antibiotics wisely, using personalized medicine approaches, and collaborating between laboratory scientists and clinicians to improve patient outcomes.

Background

The 14th Course on Antimicrobials and Infectious Diseases Update took place at Hospital Clínico San Carlos in Madrid in February 2025. The course was accredited by the Community of Madrid and endorsed by major Spanish infectious disease and chemotherapy societies. It brought together multidisciplinary healthcare professionals to discuss recent advances in bacteriology, mycology, and virology.

Objective

To provide a comprehensive update on the most relevant aspects of antimicrobial therapy and infectious diseases management. The course aimed to review diagnostic and therapeutic advances, including new β-lactamase inhibitors, rapid diagnostic technologies, and treatment strategies for resistant pathogens.

Results

The course successfully covered diagnostic innovations including monocyte distribution width biomarkers, new β-lactamase inhibitors (enmetazobactam, avibactam, relebactam, durlobactam, zidebactam, nacubactam, vaborbactam, taniborbactam, xeruborbactam), rapid diagnostic technologies, syndromic platforms, and invasive fungal infection diagnosis. Therapeutic discussions included optimization strategies for metalloenzyme-producing bacteria, nosocomial peritonitis management, and advances in cytomegalovirus and HIV treatment.

Conclusion

The XIV updating course provided comprehensive evidence-based recommendations for managing antimicrobial-resistant infections and optimizing diagnostic and therapeutic approaches. The expanded use of new β-lactamase inhibitors, rapid diagnostic technologies, and personalized treatment strategies represent crucial advances in modern infectious diseases management.
  • Published in:Rev Esp Quimioter (Spanish Journal of Chemotherapy),
  • Study Type:Review, Educational Course Summary,
  • Source: PMID: 41159223, DOI: 10.37201/req/s01.00.2025
Scroll to Top